Tags

Type your tag names separated by a space and hit enter

N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension.
Clin Rheumatol. 2008 May; 27(5):655-8.CR

Abstract

The purpose of our study was to investigate the effect of bosentan treatment on surrogate markers in patients with systemic-sclerosis-related pulmonary arterial hypertension (SScPAH). We studied ten SScPAH patients (nine female, median age 58 years, median duration of disease 9 years). Six-minute walk test (SMWT) and plasma N-terminal probrain natriuretic peptide (NT-proBNP) levels were recorded from patients at baseline and after 20 weeks under bosentan treatment. Wilcoxon paired signed rank test was applied in order to compare NT-proBNP levels and SMWT at baseline and week 20. At week 20, NT-proBNP levels were decreased from a median of 474 fmol/ml (range, 212-1407 fmol/ml) at baseline to 238 fmol/ml (range, 198-335 fmol/ml; p=0.002). Mean SMWT distance increased from a baseline median value of 323 m (range, 224-368 m) to 372 m (range, 232-530 m), representing a nonsignificant increase. Our results suggest that NT-proBNP is a biochemical surrogate marker, which could be used to evaluate the effects of bosentan or other vasodilation therapy in SScPAH.

Authors+Show Affiliations

First Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18204995

Citation

Dimitroulas, Theodoros, et al. "N-terminal Probrain Natriuretic Peptide as a Biochemical Marker in the Evaluation of Bosentan Treatment in Systemic-sclerosis-related Pulmonary Arterial Hypertension." Clinical Rheumatology, vol. 27, no. 5, 2008, pp. 655-8.
Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol. 2008;27(5):655-8.
Dimitroulas, T., Giannakoulas, G., Karvounis, H., Koliakos, G., Sfetsios, T., Dimitroula, H., & Settas, L. (2008). N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clinical Rheumatology, 27(5), 655-8. https://doi.org/10.1007/s10067-007-0828-2
Dimitroulas T, et al. N-terminal Probrain Natriuretic Peptide as a Biochemical Marker in the Evaluation of Bosentan Treatment in Systemic-sclerosis-related Pulmonary Arterial Hypertension. Clin Rheumatol. 2008;27(5):655-8. PubMed PMID: 18204995.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. AU - Dimitroulas,Theodoros, AU - Giannakoulas,Georgios, AU - Karvounis,Haralambos, AU - Koliakos,Georgios, AU - Sfetsios,Tilemahos, AU - Dimitroula,Hara, AU - Settas,Loukas, Y1 - 2008/01/18/ PY - 2007/10/19/received PY - 2007/12/17/accepted PY - 2007/12/12/revised PY - 2008/1/22/pubmed PY - 2008/10/4/medline PY - 2008/1/22/entrez SP - 655 EP - 8 JF - Clinical rheumatology JO - Clin Rheumatol VL - 27 IS - 5 N2 - The purpose of our study was to investigate the effect of bosentan treatment on surrogate markers in patients with systemic-sclerosis-related pulmonary arterial hypertension (SScPAH). We studied ten SScPAH patients (nine female, median age 58 years, median duration of disease 9 years). Six-minute walk test (SMWT) and plasma N-terminal probrain natriuretic peptide (NT-proBNP) levels were recorded from patients at baseline and after 20 weeks under bosentan treatment. Wilcoxon paired signed rank test was applied in order to compare NT-proBNP levels and SMWT at baseline and week 20. At week 20, NT-proBNP levels were decreased from a median of 474 fmol/ml (range, 212-1407 fmol/ml) at baseline to 238 fmol/ml (range, 198-335 fmol/ml; p=0.002). Mean SMWT distance increased from a baseline median value of 323 m (range, 224-368 m) to 372 m (range, 232-530 m), representing a nonsignificant increase. Our results suggest that NT-proBNP is a biochemical surrogate marker, which could be used to evaluate the effects of bosentan or other vasodilation therapy in SScPAH. SN - 0770-3198 UR - https://www.unboundmedicine.com/medline/citation/18204995/N_terminal_probrain_natriuretic_peptide_as_a_biochemical_marker_in_the_evaluation_of_bosentan_treatment_in_systemic_sclerosis_related_pulmonary_arterial_hypertension_ L2 - https://dx.doi.org/10.1007/s10067-007-0828-2 DB - PRIME DP - Unbound Medicine ER -